Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy ...

Novo Nordisk, the maker of Wegovy, will focus on commercial strategy and cost reduction. This decision follows a profit ...

Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

When Novo Nordisk A/S announced it was hunting for a replacement chief executive officer to revive its fortunes, the weight-loss drug maker — whose value has dropped by about two thirds in the past ...